China is a high strategic priority market for global life sciences investors and companies. To better serve our clients on their cutting-edge issues in this marketplace, Ropes & Gray has provided a unique resource – an exceptional and seamless cross-practice team with market-leading corporate/M&A, intellectual property, regulatory and compliance practitioners, all of whom are based on the ground in China. We routinely advise clients on regulatory matters that arise in connection with investment and M&A transactions, as well as joint venture, licensing and complex commercial arrangements. We also provide regulatory counseling to some of the world’s largest life sciences companies on matters involving China’s regulatory agencies, including the China Food and Drug Administration (CFDA), the Ministry of Health (MOH) and the State Administration of Industry and Commerce (SAIC).

FDA @ Ropes & Gray is designed to serve as your one-stop resource for up-to-date analysis related to regulatory developments in China. For more information, please click on the links located to the left.  We continually update the links with the most current resources available, and we encourage you to regularly consult these pages.

Cookie Settings